阿尔茨海默病风险变体与粉样β相互作用,调节单细胞功能
Zena K Chatila1,2, Elizabeth M Bradshaw1,2,3
1Division of Translational Neurobiology, Department of Neurology, Columbia University Irving Medical Center, 630 West 168th Street, New York, NY 10032, USA.
Cells
|December 24, 2025
概括
与阿尔茨海默氏症 (AD) 相关的遗传变异会损害单细胞免疫功能,包括细胞和TREM2表达. 这表明外围单细胞,如微质细胞,在AD病变发生过程中至关重要.
科学领域:
- 神经免疫学 神经免疫学
- 阿尔茨海默氏症疾病的遗传学
- 具有天生的免疫力.
背景情况:
- 遗传学在阿尔茨海默病 (AD) 中涉及失调的先天免疫力.
- 与微质相比,外围髓状细胞,特别是单细胞在阿尔茨海默病中没有得到充分的研究.
- 特定的AD风险位点CD33和SPI1是调查的潜在目标.
研究的目的:
- 在单细胞中研究AD风险变异的功能融合 (CD33中的rs3865444,SPI1中的rs1057233).
- 检查这些变体在对粉样ββ1-42 (Aβ1-42) 刺激的反应中的作用.
- 确定这些遗传因素是否会影响单细胞免疫能力.
主要方法:
- 从健康个体的外周血液单核细胞 (PBMC) 中分离出来的单细胞.
- 刺激的单细胞与聚合的粉样β1-42 (Aβ1-42).
- 评估了单细胞上的细胞和TREM2表达.
主要成果:
- 在Aβ刺激下确定了CD33和SPI1AD风险变体的功能融合.
- 在携带这些风险变异的单细胞中观察到减少了细胞形成.
- 发现与这些变体相关的表面TREM2表达的丧失.
结论:
- 在CD33和SPI1中的AD风险变异在暴露于Aβ.Aβ的单细胞中功能趋同.
- 这些变体通过损害细胞和TREM2表达来降低髓状细胞的适应性.
- 外围单细胞在遗传和功能上与阿尔茨海默病风险有关,强调它们在疾病易感性和进展中的作用.
关键词:
粉样蛋白-β1-42的吸收方式CD3333 CD3333 CD3333 CD3333 CD33 CD33 CD33 CD33 CD33 CD33 CD33 CD33 CD33 CD33 CD33 CD33 CD33 CD33 CD33在PU.1中,PU.在TREM2中,我们可以使用TREM2.人类单细胞.更多相关视频
09:41Quantification of Monocyte Transmigration and Foam Cell Formation from Individuals with Chronic Inflammatory Conditions
Published on: October 17, 2017
13.8K
04:41Mapping Alzheimer's Disease Variants to Their Target Genes Using Computational Analysis of Chromatin Configuration
Published on: January 9, 2020
19.3K
相关概念视频
01:26Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
01:22Alzheimer's Disease: Treatment
744
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
744
03:03Amyloid Fibrils
11.5K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
11.5K
03:03Amyloid Fibrils
6.2K
6.2K